MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TRINER, L.
Right arrow Articles by VEROSKY, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TRINER, L.
Right arrow Articles by VEROSKY, M.

Molecular Pharmacology, Vol 13, 976-979, Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics

The Action of Halothane on Adenylate Cyclase

LUBOS TRINER 1, YVONNE VULLIEMOZ 1, and MARIAGNES VEROSKY 1

1 Department of Anesthesiology, Columbia University College of Physicians and Surgeons, New York, New York 10032

Halothane, at concentrations of from 1-10 volume %, significantly increased adenylate cyclase activity in rat uterine homogenates. The activation of adenylate cyclase by halothane was not altered by propranolol. The inhibitory effect of this beta adrenergic blocking compound on isoproterenol-stimulated adenylate cyclase was not changed by halothane, while the stimulation of adenylate cyclase by isoproterenol, including the maximally effective concentration, was enhanced. The activation of the enzyme by other agonists—prostaglandin E1, sodium fluoride, and 5'-guanylylimidodiphosphate—was also markedly increased by halothane at each concentration of the agonists tested, including maximally effective concentrations. It is proposed that halothane exerts its action on uterine adenylate cyclase through conformational changes of the catalytic unit, resulting in a higher activity of the enzyme.

Note:
ACKNOWLEDGMENTS The authors thank Mrs. Olga Zak and Miss Gunilla Thulin for their excellent technical assistance.

Submitted on February 28, 1977
Accepted on April 21, 1977







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics